LJ don't seem to be controlling the price (at the moment). There is just a lack of interest (at the moment). It would seem that investors and in particular large pharmas doubt that a commercial application of ddRNAi technology is going to be viable in a time-frame that will substantially benefit BLT.
What is needed is a "breakthrough" that will speed up the development and deployment of a ddRNAi therapeutic. I thought that the research referred to in the "this could be it" posting in this forum was possibly the breakthrough but it seems that I got that wrong.
What will boost the sp will be an announcement of a partner for the HIV stem cell project.
May be BLT should do a roadshow in China and see if they can get a Chinese pharma to buy them?
BLT Price at posting:
2.4¢ Sentiment: Hold Disclosure: Held